Results 271 to 280 of about 2,892,311 (358)

Induction of hepatitis B core protein aggregation targeting an unconventional binding site. [PDF]

Elife
Khayenko V, Makbul C, Schulte C, Hemmelmann N, Kachler S, Böttcher B, Maric HM.   +6 more
europepmc   +1 more source

Bovine serum albumin. Study of the fatty acid and steroid binding sites using spin-labeled lipids.

, 1975
Joel D. Morrisett, Henry J. Pownall, AM Gotto   +2 more
openalex   +1 more source

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich, Tilman Schneider‐Hohendorf, Eric Baetscher, Evan L. Riddle, Marie Deffner, Emily Katsnelson, Janine Ferrant‐Orgettas, Julie Czerkowicz, John Anderson, Susan E. Goelz, Nicholas Schwab   +10 more
wiley   +1 more source

Allelic dropout in the endoglin (<i>ENG</i>) gene caused by common duplication beyond the primer binding site. [PDF]

Front Genet
Shestak AG, Rumyantseva VA, Zaklyazminskaya EV.   +2 more
europepmc   +1 more source

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 (SOD1) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss. Objective Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well ...
Mukesh Gautam, Ali Laith, Aslihan Gunel, Melda Yilmaz, Nazli Basak, Halil Idrisoglu, P. Hande Ozdinler   +6 more
wiley   +1 more source

A common TBP-binding site mutation elevates fetal hemoglobin levels by competitive globin switching change in β-thalassemia. [PDF]

Blood Adv
Song M, Wei X, Luo H, Wang J, Ye Y, Qin L, Niu C, Long Y, Wang X, Shao C, Yu M, Gu F, Zhang X, Xu X.   +13 more
europepmc   +1 more source

CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Neuronal pentraxin 2 (NPTX2) is a synaptic protein involved in synaptic plasticity and regulation of neuronal excitability. Lower baseline cerebrospinal fluid (CSF) NPTX2 levels have been shown to be associated with an earlier onset of mild cognitive impairment (MCI), a pre‐dementia syndrome, even after CSF Alzheimer's Disease (AD)
Juan P. Vazquez, Corinne Pettigrew, Yuxin Zhu, Claire Anderson, Guray Erus, Christos Davatzikos, Michael Miller, Abhay Moghekar, Sungtaek Oh, Chan‐Hyun Na, Marilyn Albert, Paul Worley, Anja Soldan   +12 more
wiley   +1 more source

Coevolving residues distant from the ligand binding site are involved in GAF domain function. [PDF]

Commun Chem
Ahmed WS, Geethakumari AM, Sultana A, Tiwari A, Altamash T, Arshad N, Visweswariah SS, Biswas KH.   +7 more
europepmc   +1 more source

Clinical Characteristics and Outcomes of Early‐Onset Versus Late‐Onset LGI1‐Antibody Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Leucine‐rich glioma‐inactivated 1 antibody (LGI1‐Ab) encephalitis predominantly affected older individuals, but has also been reported in younger patients. However, the demographic, clinical, and prognostic characteristics of early‐onset LGI1‐Ab encephalitis have yet to be systematically elucidated. This study aims to systematically
Yu Kong, Shasha Yu, Jing Zhang, Yu Zu, Yujing Zhang, Jing Lv, Xuyang Cao, Xuedan Feng   +7 more
wiley   +1 more source

Identification of potential human targets for epigallocatechin gallate through a novel protein binding site screening approach. [PDF]

J Mol Model
Hirci J, Škufca S, Kunej T, Janežič D, Konc J.   +4 more
europepmc   +1 more source